Publications

Collaborations and publications are strong proofs of the relevance of our research.
H-Factors : Dr. Laurent Meijer (69) / Pr. Hervé Galons (27)

Cystic Fibrosis (CF)

  1. Norez, C., Vandebrouck, C., Bertrand, J., Noel, S., Durieu, E., Oumata, N., Galons, H., Antigny, F., Chatelier, A., Bois, P., Meijer, L. and Becq, F., 2014. Roscovitine is a proteostasis regulator that corrects the trafficking defect of F508del-CFTR by a CDK-independent mechanism. Br. J. Pharmacol. 171, 4831-4849.
  2. A Phase II, dose ranging, multicenter, double-blind, placebo controlled study to evaluate safety and effects of (R)-roscovitine in subjects with Cystic Fibrosis, homozygous for the F508del-CFTR mutation and chronically infected with Pseudomonas aeruginosa, a study involving 36 CF patients (24 treated, 12 controls). ANSM authorization Sept. 15, 2015. https://clinicaltrials.gov/ct2/show/NCT02649751?term=roscovitine&rank=1
  3. Riazanski, V., Gabdulkhakova, A.G., Boynton, L.S., Eguchi, R.R., Deriy, L.V., Hogarth, D.K., Loaëc, N., Oumata, N., Galons, H., Brown, M.E., Shevchenko, P., Gallan, A.J., Yoo, S.G., Naren, A.P., Villereal, M.L., Beacham, D.W., Bindokas, V.P., Birnbaumer, L., Meijer, L. and Nelson, D.J., 2015. TRPC6 channel translocation into phagosomal membrane augments phagosomal function. Proc. Natl. Acad. Sci. USA 112, E6486-6495.
  4. Meijer, L., Nelson, D., Riazanski, V., Gabdoulkhakova, A.G., Hery-Arnaud, G., Leberre, R., Loaëc, N., Oumata, N., Galons, H., Nowak, E., Gueganton, L., Dorothée, G., Prochazkova, M., Hall, B., Kulkarni, A.B., Gray, R.D., Rossi, A.G., Witko-Sarsat, V., Norez, C., Becq, F., Ravel, D., Mottier, D. and Rault, G., 2016. Modulating innate and adaptative immunity by (R)-roscovitine: potential therapeutic opportunity in cystic fibrosis J. Innate Immunity 8, 330-349.

Polycystic Kidney Disease (PKD)

  1. Bukanov, N.O., Smith, L.A., Klinger, K.W., Ledbetter, S.R. and Ibraghimov-Beskrovnaya, O., 2006. Long-lasting arrest of murine polycystic kidney disease with CDK inhibitor roscovitine. Nature 444, 949-952.
  2. Bukanov, N.O., Moreno, S.E., Natoli, T.A., Rogers, K.A., Smith, L.A., Ledbetter, S.R., Oumata, N., Galons, Meijer, L. and Oxana Ibraghimov-Beskrovnaya, O., 2012. CDK inhibitors R-roscovitine and S-CR8 effectively inhibit renal and hepatic cystogenesis in an orthologous model of ADPKD. Cell Cycle 11, 4040-4046.
  3. Husson, H., Moreno, S., Smith, L.A., Smith, M.M., Russo, R.J., Carlson, G., Pitstick, R., Sergeev, M., Ledbetter, S.R., Bukanov, N.O., Shah, J., Billot, K., Meijer, L., Beier, D.R. and Ibraghimov-Beskrovnaya, O., 2016. Reduction of ciliary length through pharmacologic or genetic inhibition of CDK5 attenuates polycystic kidney disease in a model of nephronophthisis. Human Mol. Med., in press.

Alzheimer’s Disease (AD) & Down Syndrome (DS)

  1. Fant, X., Durieu, E., Chicanne, G., Payrastre, B., Sbrissa, D., Shisheva, A., Limanton, E., Carreaux, F., Bazureau, J.P. and Meijer, L., 2014. Cdc-like/dual-specificity tyrosine phosphorylation-regulated kinases Leucettine L41 induces mTOR-dependent autophagy: implication for Alzheimer’s disease. Mol. Pharmacol. 85, 441-450. 
  2. Hochard, A., Oumata, N., Durieu, E., Bettayeb, K., Gloulou, O., Fant, X., Buron, N., Porceddu, M., Borgne, A., Galons, H., Flajolet, M. and Meijer, L., 2013. Aftins increase amyloid-β42, lower amyloid-β38 and do not alter amyloid-β40 in vitro production: towards a chemical model of Alzheimer’s disease? J. Alzheimer’s Disease 35, 107-120.
  3. Tahtouh, T., Elkins, J.M., Filippakopoulos, P., Soundararajan, M., Burgy, G., Durieu, E., Cochet, C., Schmid, R.S., Lo, D.C., Delhommel, F., Oberholzer, A.E., Pearl, L.H., Carreaux, F., Bazureau, J.P., Knapp, S. and Meijer, L., 2012. Selectivity, cocrystal structures and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B. J. Med. Chem. 55, 9312-9330.
  4. Debdab, M., Carreaux, F., Renault, S., Soundararajan, M., Fedorov, O., Filippakopoulos, P., Lozach, O., Babault, L., Tahtouh, T., Baratte, B., Ogawa, Y., Hagiwara, M., Eisenreich, A., Rauch, U., Knapp, S., Meijer, L. and Bazureau, J.P., 2011. Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B. Modulation of alternative pre-RNA splicing. J. Med. Chem. 54, 4172-4186.
  5. Portelius, E., Durieu, E., Bodin, M., Cam, M., Pannee, J., Leuxe, C., Mabondzo, A., Oumata, N., Galons, H., Lee, J., Chang, Y.T., Stüber, K., Koch, P., Fontaine, G., Potier, M.C., Manousopoulou, A., Garbis, S., Covaci, A., Van Dam, D., De Deyn, P., Karg, F., Flajolet, M., Omori, C., Hata, S, Suzuki, T., Blennow, K., Zetterberg, H. and Meijer, L., 2016. Specific triazine herbicides induce amyloid β 42 production. J. Alzheimer’s Disease 54, in press.

DYRK Conference

March 28 – April 1st 2017 | Saint Malo, France

Download PDF (1,4MB)   Event Website